CD30-targeted antibody-drug conjugate 
Welcome,         Profile    Billing    Logout  
  Companies   Products    Products    Diseases    Trials    News 


123»
  • ||||||||||  Journal:  Standardization of CD30 immunohistochemistry staining among three automated immunostaining platforms. (Pubmed Central) -  Aug 22, 2024   
    The concordance rates among three platforms in the evaluation of "positive" or "negative" were 100% and 97% when the cutoff values were 1% and 10% respectively, if using 400-diluted antibody in B III and 100-diluted antibody in DO. This study demonstrated the feasibility of equalizing CD30 staining of PTCLs among different platforms by adjusting protocols.
  • ||||||||||  Adcetris (brentuximab vedotin) / Takeda, Pfizer
    Retrospective data, Journal:  Histopathologic and Clinical Characterization of Brentuximab Vedotin-associated Rash. (Pubmed Central) -  Aug 15, 2024   
    In 17 specimens with immunohistochemistry, the CD4:CD8 ratio in intraepidermal lymphocytes was relatively normal (1-6:1) in 65% (11/17) and 1:1 in 35% (6/17), demonstrating a trend toward increased CD8-positive cells compared with baseline CTCL. We have identified features that can help distinguish BVAR from a patient's CTCL, which can, in turn, help guide appropriate clinical management.
  • ||||||||||  Poteligeo (mogamulizumab-kpkc) / Kyowa Kirin, Campath (alemtuzumab) / Sanofi, Adcetris (brentuximab vedotin) / Takeda, Pfizer
    The Promise of Immunotherapies in T-Cell Lymphoma (Level 3, 370 C) -  Jul 5, 2024 - Abstract #SOHO2024SOHO_15;    
    We have identified features that can help distinguish BVAR from a patient's CTCL, which can, in turn, help guide appropriate clinical management. As of now, two
  • ||||||||||  Adcetris (brentuximab vedotin) / Takeda, Pfizer
    Review, Journal:  Pediatric and Adolescent Hodgkin Lymphoma: Paving the Way for Standards of Care and Shared Decision Making. (Pubmed Central) -  May 24, 2024   
    The advent of checkpoint inhibitors and the CD30-targeted antibody drug conjugate, brentuximab vedotin, has provided new options for de-escalation of conventional therapies associated with late effects in survivors treated at a young age...Given excellent survival outcomes, decisions about treatment in classic HL should be collaborative and attention to long-term survivorship needs should remain a high priority. Patient-reported outcomes remain an important tool to aid clinicians working with survivors to optimize health status and related quality of life for decades after HL therapy.
  • ||||||||||  Adcetris (brentuximab vedotin) / Takeda, Pfizer
    Review, Journal:  Aggressive T-cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management. (Pubmed Central) -  Feb 2, 2024   
    This includes the CD30 directed antibody drug conjugate brentuximab vedotin...The use of checkpoint inhibitors in the treatment of PTCL is still controversial, with best results seen in cases of extranodal natural killer cell/T-cell lymphoma. Bispecific antibody-based treatments and chimeric antigen receptor cell-based therapies are in clinical trials.
  • ||||||||||  Adcetris (brentuximab vedotin) / Seagen, Takeda
    How is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023? (SDCC - Ballroom 20CD) -  Oct 22, 2023 - Abstract #ASH2023ASH_670;    
    Natalie Grover will discuss the treatment of relapsed/refractory cHL in patients whose disease has progressed after brentuximab vedotin and PD-1 blockade. Using a case-based approach, therapeutic options for these challenging cases will be presented, including the role of cytotoxic chemotherapy, allogeneic stem cell transplantation, and clinical trial results with novel agents, including chimeric antigen receptor T-cells.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Adcetris (brentuximab vedotin) / Seagen, Takeda
    Activated regulatory T cells in solid tumors express CD30, which are selectively targeted by the novel anti-CD30 antibody drug conjugate SGN-35T (Exhibit Hall B) -  Sep 27, 2023 - Abstract #SITC2023SITC_1457;    
    P2
    It is currently being tested in combination with pembrolizumab for the ability to deplete Tregs and increase immune checkpoint activity in anti-PD-1-refractory metastatic melanoma and NSCLC (NCT04609566)...Conclusions Thus, the cytotoxic activity of SGN-35T on CD30-expressing Tregs is likely a combination of the enrichment of CD30 expression on activated Tregs coupled with reduced drug efflux capacity. Together, these data support future clinical investigation of SGN-35T in combination with anti-PD-1/PD-L1 checkpoint inhibitors in solid tumors.
  • ||||||||||  Adcetris (brentuximab vedotin) / Seagen, Takeda, Opdivo (nivolumab) / Ono Pharma, BMS, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
    Targeted immunotherapy and checkpoint blockade in children, adolescents, and young adults with lymphoma: RADICAL hodgkin cohort (Exhibit Hall B) -  Sep 27, 2023 - Abstract #SITC2023SITC_1020;    
    P2
    Recently, we completed a phase 2 trial evaluating the use of an antibody-drug conjugate targeting CD30 (brentuximab vedotin, Bv) and an anti-CD20 antibody targeting regulatory B-cells (rituximab, RTX) added to risk-adapted chemotherapy in newly diagnosed cHL CAYA patients...RERs by FDG-PET scan receive 4 cycles of Bv-NVD-R; SERs receive 2 cycles of Bv, nivolumab, doxorubicin, vinblastine, dacarbazine and RTX (Bv-NAVD-R), followed by 4 cycles of Bv-NVD-R...Conclusions Targeting the Hodgkin Reed-Sternberg cell as well as the TME (regulatory B-cells) and PD1/PD-L1 axis is a promising approach in CAYA with cHL. (NCT05253495).
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Adcetris (brentuximab vedotin) / Seagen, Takeda, Opdivo (nivolumab) / Ono Pharma, BMS
    Journal:  Incorporating novel agents into frontline treatment of Hodgkin lymphoma. (Pubmed Central) -  Dec 10, 2022   
    Incorporation of these potent, targeted immunotherapies into frontline therapy may improve outcomes, may allow for de-escalation of therapy without sacrificing efficacy to reduce treatment complications, and may allow for well-tolerated and targeted escalation of therapy for patients demonstrating an insufficient response. In this article, we provide a case-based approach to the use of novel agents in the frontline treatment of cHL.
  • ||||||||||  Adcetris (brentuximab vedotin) / Seagen, Takeda
    Journal:  Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma. (Pubmed Central) -  Nov 9, 2022   
    P3
    The addition of brentuximab vedotin to standard chemotherapy resulted in superior efficacy, with a 59% lower risk of an event or death, and no increase in the incidence of toxic effects at 3 years. (Funded by the National Institutes of Health and others; AHOD1331 ClinicalTrials.gov number, NCT02166463.).
  • ||||||||||  Adcetris (brentuximab vedotin) / Seagen, Takeda
    Peripheral Neuropathy in Children with High Risk Hodgkin Lymphoma (HL): The Role of Protocol-Stipulated Dose Modification in the Children's Oncology Group (COG) AHOD1331 Study (ENMCC - Hall D) -  Nov 4, 2022 - Abstract #ASH2022ASH_4294;    
    P3
    Background Peripheral neuropathy (PN) is commonly associated with several classes of chemotherapy, including vinca alkaloids and the novel anti-CD30-directed antibody-drug conjugate, Brentuximab vedotin (Bv)...In the 2018 Echelon-1 study, rates of PN among adults with advanced stage HL were 67% in the Bv arm as compared to 43% in the control arm (Connors, 2018) with dose modifications at the discretion of the treating physician of 66% for Bv and 57% for vinblastine (VBL)...While there were no significant differences in the rate of PN between study arms, we found shorter median time to dose modification in the exp arm, corresponding to the second treatment cycle, as compared to the 3rd cycle for the std arm. Despite dose modifications of vincristine and Bv as management strategies for PN in the experimental arm, patients treated with Bv-AVEPC had superior disease control in children with high-risk HL.
  • ||||||||||  Adcetris (brentuximab vedotin) / Seagen, Takeda
    Acute Interstitial Nephritis Secondary to Brentuximab (Exhibit Hall, Orange County Convention Center, West Building) -  Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_3504;    
    The key prognosticating factor for renal recovery is the extend of renal fibrosis. A renal biopsy showing interstitial edema, inflammatory infiltrate comprised of lymphocytes, occasional eosinophils, and rare neutrophils, and tubulitis.
  • ||||||||||  Adcetris (brentuximab vedotin) / Seagen, Takeda
    Journal:  Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma. (Pubmed Central) -  Oct 5, 2022   
    A renal biopsy showing interstitial edema, inflammatory infiltrate comprised of lymphocytes, occasional eosinophils, and rare neutrophils, and tubulitis. In this analysis of studies across a range of CD30-expressing lymphomas, CD30 expression alone, as measured by standard IHC, does not predict clinical benefit from BV, making the determination of a threshold level of expression uncertain.
  • ||||||||||  Adcetris (brentuximab vedotin) / Seagen, Takeda
    Journal:  Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. (Pubmed Central) -  Aug 12, 2022   
    P3
    Patients who received A+AVD for the treatment of stage III or IV Hodgkin's lymphoma had a survival advantage over those who received ABVD. (Funded by Takeda Development Center Americas and Seagen; ECHELON-1 ClinicalTrials.gov number, NCT01712490; EudraCT number, 2011-005450-60.).
  • ||||||||||  Adcetris (brentuximab vedotin) / Seagen, Takeda
    Journal:  Inhibitors of A Disintegrin And Metalloproteinases-10 reduce Hodgkin lymphoma cell growth in 3D microenvironments and enhance brentuximab-vedotin effect. (Pubmed Central) -  Apr 5, 2022   
    In these 3D systems we found that: 1) the ADAM10 inhibitors LT4 and MN8 reduce ATP content or glucose consumption, related to cell proliferation, increasing lactate dehydrogenase (LDH) release as a cell damage hallmark; 2) these events are paralleled by mixed spheroids size reduction and inhibition of CD30 and TNFα shedding; 3) the effects observed can be reproduced in repopulated HL LN-derived matrix or collagen scaffolds; 4) ADAM10 inhibitors enhance the antilymphoma effect of the anti-CD30 ADC BtxVed both in conventional cultures and in repopulated scaffolds. Thus, we provide evidence for direct and combined anti-lymphoma effect of ADAM10 inhibitors with BtxVed, leading to improvement of ADC effects; this is documented in 3D models recapitulating features of LN microenvironment, that can be proposed as reliable tool for antilymphoma drug testing.
  • ||||||||||  Adcetris (brentuximab vedotin) / Seagen, Takeda
    P2 data, Journal:  Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors. (Pubmed Central) -  Feb 17, 2022   
    6 patients achieved radiographic stable disease (range, 9-14.9 weeks), 5 had elevated AFP or hCG at trial entry and all 5 had transient > 50% decline in baseline AFP/hCG: 4 had CD30 -ve and 2 had CD30 + ve staining; 10 patients had progression of disease as their best response; 2 were not evaluable for response. Conclusion Brentuximab vedotin does not appear to have clinically meaningful single-agent activity in patients with refractory GCT.
  • ||||||||||  Adcetris (brentuximab vedotin) / Seagen, Takeda
    Journal:  How to choose first salvage therapy in Hodgkin lymphoma: traditional chemotherapy vs novel agents. (Pubmed Central) -  Feb 17, 2022   
    In the past decade, novel therapies have been developed, such as the CD30-directed antibody-drug conjugate brentuximab vedotin and immune checkpoint inhibitors, which have greatly extended the treatment possibilities for patients with R/R cHL...In this review, we discuss treatment options for patients with R/R cHL in different settings: patients with a first relapse, primary refractory disease, and in patients who are ineligible or unfit for ASCT. Results of clinical trials investigating novel therapies or strategies published over the past 5 years are summarized.
  • ||||||||||  Adcetris (brentuximab vedotin) / Seagen, Takeda
    BRENTUXIMAB VEDOTIN (BV) FOLLOWED BY BENDAMUSTINE SUPERCHARGE (BS) FOR REFRACTORY OR RELAPSED (R/R) CLASSICAL-HODGKIN LYMPHOMA (C-HL): 3-YEAR UPDATE OF THE BV+BS-21 STUDY () -  Dec 25, 2021 - Abstract #SIE2021SIE_114;    
    Ten patients (29%) experienced grade ≥3 treatment-related adverse events consisting of cytomegalovirus reactivation (median CMV-DNA, 1810 IU/mL; range, 620-170 000 IU/mL) with fever (successfully treated with preemptive therapy with valganciclovir) in 7 cases and neutropenia in 3 cases, all resolved without requiring hospitalization...In this last sub-group, for 12 patients PBSC were previously harvested after two courses of Ifosfamide, Gemcitabine, Vinorelbine and Prednisolone; in the remaining 10 cases PBSC were successfully collected after Bv+Bs21, with mobilization with G-CSF, vinorelbine-cyclophosphamide and/or plerixafor regimen...At a median follow-up of 42 months (1-94 months) from Bv+Bs-21 regimen termination, the estimated 3-year PFS of the entire population was 94% (95% confidence interval, 84.4%-100%). In conclusion, our clinical data indicate that bendamustine (an old and low-cost cytotoxic agent) used in a new schedule modality (i.e., administered at increased dose and afterward the first-in-class antibody drug conjugate targeting CD30), has highly synergistic activity in outpatient salvage regimen against R/R HRS cells of patients aged <60 years.
  • ||||||||||  Adcetris (brentuximab vedotin) / Seagen, Takeda
    Trial in Progress: Real-World Safety and Effectiveness of Brentuximab Vedotin in Adults with CD30+ Lymphoma in China () -  Nov 24, 2021 - Abstract #ASH2021ASH_6665;    
    P=N/A
    Secondary endpoints include adverse events, adverse drug reaction, dose adjustment, characteristics of patients receiving BV, use of BV, number of BV cycles administered, disease characteristics, time to next treatment, overall response rate, duration of response, progression free survival rate, overall survival rate, quality of life and cost-effectiveness ratio. Descriptive analysis will be performed for data analysis.
  • ||||||||||  Adcetris (brentuximab vedotin) / Seagen, Takeda
    New Onset Persistent Hyperglycemia with Initiation of Brentuximab Treatment () -  Nov 24, 2021 - Abstract #ASH2021ASH_6260;    
    However, her last dose of dexamethasone was given more than ten days prior to her most recent FSBG reading of 220 mg/dL, so steroid-induced diabetes was deemed less likely...For many years, the standard of Hodgkin Lymphoma treatment consisted of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD)...Regardless of the mechanism of action, the above case report demonstrates a need to monitor blood glucose levels carefully during the initiation of BV therapy, especially in those individuals who have risk factors such as obesity or pre-diabetes mellitus. Future studies may further address the mechanism of hyperglycemia from BV and if the resultant diabetes is reversible.